🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

GBM AGILE Spotlight 🧠✨ Dr. Eudocia Lee, Co-PI Paxalisib Arm GBM AGILE, Director of Clinical Research, Neuro-Oncology, Dana Farber Cancer Institute, and Associate Professor of Neurology, Harvard Medical School, explains the benefits of a platform trial approach to evaluating

New White Paper! INNOVATION IN ACTION: Data Management Strategies for Master Protocols and Adaptive Platform Trials is here! 📄💡 Master protocols are transforming clinical trials - evaluating multiple therapies under one adaptable framework for faster results, lower costs, and

As Brain Tumor Awareness Month comes to a close, Dr. Eudocia Lee, Co-PI of the Paxalisib Arm in #GBMAGILE and Director of Clinical Research in Neuro-Oncology at Dana-Farber, reflects on hope fueled by the relentless pursuit of researchers around the world who are working to

GCAR team and #GBMAGILE investigators at #ASCO2025 with the GBM AGILE trial in progress poster 🧠 To learn more about GBM AGILE, a global adaptive platform trial for patients with newly diagnosed and recurrent #glioblastoma, visit: gcaresearch.org/research/gbm-a…

GCAR’s Meredith Buxton and Rob Murray with Anna Berkenblit, MD, MMSc, Chief Scientific and Medical Officer, PanCAN at #ASCO2025

That’s a wrap! #ASCO2025 It was wonderful to see and spend time with clinical leadership and collaborators who are partnering with GCAR to advance new #clinicaltrial initiatives in #OvarianCancer, #PancreaticCancer, #BiliaryTractCancer, and #Neurofibromatosis – efficient,

June marks PTSD Awareness Month - a month dedicated to raising awareness about posttraumatic stress disorder (PTSD), its profound impact on individuals and families, and the importance of seeking help and treatment. In collaboration with the U.S. Department of Defense, GCAR is

GBM AGILE leadership gathering at #ASCO2025 Trial leadership met to discuss new trial innovations and to advance exciting plans to maximize learning from every patient 🧬🔎 Since launching in 2019, seven investigational therapies have entered the trial, and sites in six

Good looking bunch! GBM AGILE has exciting new therapies in the pipeline and is rapidly becoming a repository of massive amounts of data with plans for extensive molecular profiling and translational work. Kudos to the Global Coalition for Adaptive Research team!

Did you know that veterans are more likely than civilians to have posttraumatic stress disorder (PTSD)? PTSD affects approximately 7 out of every 100 veterans. Only two medications - paroxetine and sertraline - are FDA-approved for the treatment of PTSD. While other medications

The M-PACT study is recruiting US military active-duty service members and veterans with PTSD at multiple trial locations. To learn more about trial eligibility, visit: ptsdclinicaltrial.org/eligibility/ For additional trial information, visit: gcaresearch.org/research/us-de… #PTSD

Join the effort to successfully treat posttraumatic stress disorder (PTSD) through research. The M-PACT study is investigating how study medications can help people with PTSD. Accepting trial participants at multiple locations in the US with new locations being added. If you or

Be the first to know what’s next at GCAR! Subscribe to GCAR’s newsletter for exclusive updates on our cutting-edge platform trials, research initiatives, and the latest developments – delivered straight to your inbox. Join a global community of researchers, clinicians,

Last week trial leadership attended the International Conference on Brain Tumor Research and Therapy in Hokkaido, Japan to present updates on GBM AGILE, a global seamless phase 2/3 clinical trial for patients with newly diagnosed and recurrent #glioblastoma (Left to Right)

Today, on #GBMDay, we stand with everyone affected by #glioblastoma – the most aggressive and deadliest form of brain cancer, with a median survival of just 9 months and a 5-year survival rate of only 7.1%. GCAR is proud to lead #GBMAGILE, an innovative global trial

Rob Murray, Chief Business and Strategy Officer, GCAR, with Ingo Mellinghoff, GBM AGILE Arm Selection Committee Co-Chair, and David Arons, President & CEO, National Brain Tumor Society at the NBTS #GBMDay. Also in attendance - Naween Tamjidi, Senior Manager, Trial Operations, GCAR. A huge thank you